Mesoblast (ASX:MSB) logged $0.0444 in loss per share for fiscal 2026, compared with a loss of $0.0846 a year ago, a Thursday filing showed.
For the 12 months ended June 30, revenue was $120.3 million versus $17.2 million previously, the Australia-listed biotechnology company added.
Shares rose past 2% in morning trade Thursday.